For the year ending 2025-12-31, TARS made $451,360K in revenue. -$66,216K in net income. Net profit margin of -14.67%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 451,360 | 180,059 | ||
| Cost of sales-Product | 30,684 | - | ||
| Cost of sales | - | 12,826 | ||
| Research and development | 64,322 | 53,386 | ||
| Selling, general and administrative | 427,323 | 237,310 | ||
| Total operating expenses | 522,329 | 303,522 | ||
| Loss from operations before other income (expense) | -70,969 | -120,569 | ||
| Interest income | 15,747 | 15,014 | ||
| Interest expense | 8,935 | 7,849 | ||
| Realized/unrealized (loss) gain on equity investments | - | -591 | ||
| Change in fair value of equity warrants issued by licensee | - | -201 | ||
| Loss on debt extinguishment | 0 | -1,944 | ||
| Other income (expense), net | -202 | 586 | ||
| Total other income, net | 6,610 | 5,015 | ||
| Loss before income taxes | -64,359 | -115,554 | ||
| Provision for income taxes | 2,059 | 0 | ||
| Net loss | -66,418 | -115,554 | ||
| Unrealized gain (loss) on marketable securities and cash equivalents | 202 | 181 | ||
| Comprehensive loss | -66,216 | -115,373 | ||
| Basic EPS | -1.59 | -3.07 | ||
| Diluted EPS | -1.59 | -3.07 | ||
| Basic Average Shares | 41,784,014 | 37,604,538 | ||
| Diluted Average Shares | 41,784,014 | 37,604,538 | ||
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)